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Abstract: Glycation process occurs in protein and becomes more pronounced in diabetes when an 
increased amount of reducing sugar is present in bloodstream. Glycation of protein may cause 
conformational changes resulting in the alterations of its binding properties even though they occur 
at a distance from the binding sites. The changes in protein properties could be related to several 
pathological consequences such as diabetic and nondiabetic cardiovascular diseases, cataract, renal 
dysfunction and Alzheimer’s disease. The experiment was designed to test the impact of glycation 
process on sulfonylurea drug tolbutamide-albumin binding under physiological (T = 309 K) and 
inflammatory (T = 311 K and T = 313 K) states using fluorescence and UV-VIS spectroscopies. It was 
found in fluorescence analysis experiments that the modification of serum albumin in tryptophanyl 
and tyrosyl residues environment may affect the tolbutamide (TB) binding to albumin in subdomain 
IIA and/or IIIA (Sudlow’s site I and/or II), and also in subdomains IB and IIB. We estimated the 
binding of tolbutamide to albumin described by a mixed nature of interaction (specific and nonspecific). 
The association constants ܭ௔ (L∙mol−1) for tolbutamide at its high affinity sites on non-glycated albumin 
were in the range of 1.98–7.88 × 104 L∙mol−1 (λex = 275 nm), 1.20–1.64 × 104 L∙mol−1 (λex = 295 nm) and 
decreased to 1.24–0.42 × 104 L∙mol−1 at λex = 275 nm (T = 309 K and T = 311 K) and increased to  
2.79 × 104 L∙mol−1 at λex = 275 nm (T = 313 K) and to 4.43–6.61 × 104 L∙mol−1 at λex = 295 nm due to the 
glycation process. Temperature dependence suggests the important role of van der Waals forces 
and hydrogen bonding in hydrophobic interactions between tolbutamide and both glycated and 
non-glycated albumin. We concluded that the changes in the environment of TB binding of albumin 
in subdomain IIA and/or IIIA as well as in subdomains IB and IIB influence on therapeutic effect 
and therefore the studies of the binding of tolbutamide (in diabetes) to transporting protein under 
glycation that refers to the modification of a protein are of great importance in pharmacology and 
biochemistry. This information may lead to the development of more effective drug therapy in 
people with diabetes. 
Keywords: serum albumin glycation; tolbutamide-albumin binding; fluorescence quenching 
 
1. Introduction 
Serum albumin plays a significant role in drugs pharmacokinetics and can affect pharmacological or 
toxicity effect of the drug. The drug–serum albumin interaction is an important component in 
understanding mechanism of action and drugs distribution [1]. The capability of serum albumin to bind 
aromatic and heterocyclic compounds is largely dependent on the existence of two major binding 
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regions, namely Sudlow’s site I and II which are located within specialized cavities in subdomains 
IIA and IIIA, respectively [2]. When protein modification induced by physiological or pathological 
changes occurs, an alteration of the native conformation and efficiency of major binding sites can be 
expected [3]. Albumin is exposed to numerous structural modifications that can influence its stability, 
activity and physical and chemical properties, thus affect the functions performed by this protein [4,5]. 
Major modification concerning serum albumin is non-enzymatic glycation process that begins with 
the reaction between a reducing sugar and a free amine group on a protein. Glycation leads to the 
formation of Advanced Glycation End-products (AGEs). AGEs take part in the pathogenesis of many 
diseases related to aging and also lead to development of many diabetic complications [6]. AGEs 
exhibit a wide range of chemical structures and thereby have different biological properties some of 
them are fluorescent like pentosidine and argpyrimidine [7,8]. Based on the literature, Lys-525, 538 
and 545 (located near subdomain IIIA), Lys-414, 439, 475, Arg-410, 428, 472 (located in subdomain IIIA) 
and Lys-199, 212, 233, 276, 281, 286, and Arg-218 (located in subdomain IIA) are the main sites of 
human serum albumin (HSA) glycation [9–13]. Glucose, fructose, galactose and other reducing sugars can 
react with proteins through the Maillard reaction (glycation) and form irreversible AGEs [14,15]. 
Schalkwijk et al. wrote that the formation of AGEs is known to result from the action of various 
metabolites other than glucose, which are primarily located intracellularly and participate in the  
non-enzymatic glycation reaction at a much faster rate, such as fructose [16]. They also indicated that 
despite fructose eightfold higher reactivity, the contribution of extracellular glycation by fructose is 
considerably less than by glucose because of the low plasma concentration of fructose (5 mmol/L 
glucose vs. 35 μmol/L fructose). Intracellularly, the level fructose is elevated in many diabetic patients 
tissues where the polyol pathway is active. Furthermore, in the cells of these tissues, the concentrations of 
fructose and glucose are of the same magnitude. 
Tolbutamide (1-Butyl-3-(4-methylphenyl)sulfonylurea, TB, Scheme 1) is an oral hypoglycemic drug 
that was formerly used in a treatment of diabetes type 2. Tolbutamide is metabolized by cytochrome 
P450 2C9 (CYP2C9) [17]. At therapeutic level TB is strongly bound to plasma protein in 91–96%. 
 
Scheme 1. Chemical structure of tolbutamide (TB). 
Because the glycation may cause a number of structural changes in the spatial albumin structure 
that can affect the binding of ligands, the aim of the study was to investigate the influence of glycation 
process on tolbutamide-albumin binding in temperature corresponding to the human physiological 
(T = 309 K) and inflammatory states (T = 311 K and T = 313 K) using fluorescence and UV-VIS 
spectroscopies as a useful tools due to the high sensitivity, rapidity and ease of implementation. 
2. Results and Discussion 
2.1. The Structural Modification—Glycation of Serum Albumin 
Glycation as a result of the metabolic changes that occur during diabetes causes a number of 
structural and functional modification in serum albumin. The extent of modification that occurs in 
protein depends mainly on the time of protein incubation with reducing sugar and a type of reducing 
sugar. Fructose, as compared with glucose, reacts faster with proteins and produces more protein-
bound fluorescence than glucose [14,18]. 
In the present study, fructose has been used as a bovine serum albumin (BSA) initiator of glycation. 
In order to focus on the main albumin binding sites, Sudlow’s site I located in subdomain IIA and 
Sudlow’s site II located in subdomain IIIA, we used λex = 275 nm and λex = 295 nm excitation wavelengths. 
λex = 275 nm excites both tyrosyl and tryprophanyl residues while λex = 295 nm almost exclusively 
tryptophanyl residue. BSA contains two tryptophanyl residues, Trp-214 (subdomain IIA) and  
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Trp-135 (subdomain IB), whereas BSA tyrosyl residues are located in subdomain IA (Tyr-30), IB (Tyr-138, 
-140, -148, -150, -156, -157, and -161), IIA (Tyr-263), IIB (Tyr-319, -332, -334, -341, -353, and -370), IIIA 
(Tyr-401, -411, -452, and -497) [19]. According to the literature, sensitive to in vivo and in vitro 
glycation are albumin amino acid residues with high nucleophile properties (lysine, Lys and arginine 
(Arg)) and also a free thiol group of cysteine (Cys-34) located both around and inside of subdomains 
IIA, IIIA, IB and IA [20]. It means that the glycation process can have an influence on the main 
Sudlow’s site I and II, and the using of fluorescence quenching method with two excitation 
wavelengths (275 nm and 295 nm) allows for the analysis of these sites. Moreover, due to the BSA 
second Trp-135 residue (subdomain IB) the study of glycation impact on the environment of subdomain 
IB is possible. The influence of glycation process on albumin conformation was investigated by the 
comparison of synchronous and emission spectra recorded for non-glycated (BSA) and glycated bovine 
serum albumin (gBSA). Furthermore, the second derivative of fluorescence spectroscopy and spectral 
parameter A were first used for the identification of subtle changes in the tertiary conformation of 
proteins. Because the wavelength of λex = 295 nm excites almost entirely tryptophanyl residue while 
λex = 275 nm excites both tryptophanyl and tyrosyl residues, and it is impossible to observe separately 
the fluorescence of tyrosyl residues [21], synchronous fluorescence spectroscopy allows for the 
separation of the emission spectra originating from the Trp and Tyr residues and more specific 
information concerning the structure of protein than derived from conventional fluorescence 
spectroscopy can be obtained. Spectral parameter A has been used in order to monitor the structural 
changes in tryptophanyl residues microenvironment. According to literature data [22], the synchronous 
fluorescence spectra were obtained considering the wavelength intervals Δλ = 60 nm and Δλ = 15 nm 
to evidence the tryptophanyl and tyrosyl residues, respectively (Δλ = λem − λex). The synchronous 
fluorescence spectra of both types of fluorophores in BSA and gBSA at the selected temperature of 
309 K have been presented in Figure 1. 
 
Figure 1. Synchronous fluorescence spectra of non-glycated (BSA: — Δλ = 60 nm, -∙-∙-∙ Δλ = 15 nm) 
and glycated (gBSA: --- Δλ = 60 nm, ∙∙∙ Δλ = 15 nm) bovine serum albumin, BSA, gBSA = 5 × 10−6 mol∙L−1,  
T = 309 K. 
Synchronous fluorescence spectra of BSA and gBSA Trp and Tyr residues show single emission 
maxima at λmax = 340 nm and λmax = 300 nm, respectively (Figure 1). It is noteworthy that the synchronous 
fluorescence spectrum of glycated bovine serum albumin allowed observing an additional signal in the 
region between λem = 370 nm and 470 nm with λmax = 405 nm (for the wavelength intervals Δλ = 60 nm) 
(Figure 1). It can be concluded that this effect is caused by the formation of BSA fluorescence 
Advanced Glycation End-products (AGEs) and an additional signal derives from the fluorescent 
AGEs. To prove the impact of glycation by fructose on the formation of AGEs in bovine serum 
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albumin, fluorescence emission spectra of BSA and gBSA were recorded at excitation wavelength of 
λex = 335 nm (absorbance maximum wavelength of AGEs) (Figure 2). 
 
Figure 2. AGEs emission fluorescence spectra of non-glycated and glycated bovine serum albumin at 
λex = 335 nm, BSA, gBSA = 5 × 10−6 mol∙L−1, T = 309 K. 
Figure 2 summarizes a typical experiment comparing changes between emission florescence 
spectra of Advanced Glycation End-products coming from non-glycated and created in glycated 
albumin. Greater values of maximum fluorescence (Fmax) of AGEs were obtained for glycated albumin 
(F414nm = 302) than non-glycated (F419nm = 24). It is important to note that a widely accepted assumption is 
that greater fluorescence intensity is, the more significant protein modification occurs [23]. Argpyrimidine 
shows fluorescence maximum at about λem = 400 nm and pentosidine at λem = 375–385 nm [22]. In opposite 
to our results, S. Vetter and V. Indurthi reported that Advanced Glycation End-products of human 
serum albumin (HSA) glycated by glucose do not show typical for pentosidine or argpyrimidine 
fluorescence but red-shifted fluorescence with maxima about λem = 420 nm and λem = 435 nm 
(excitation at λex = 330 nm or λex = 365 nm), respectively [24]. The increase in the AGEs fluorescence 
intensities is accompanied by a blue-shift (Δλ = 5 nm) of maximum fluorescence at λex = 335 nm.  
This blue-shift of BSA maximum fluorescence under the glycation process by fructose makes the 
changes that AGEs environment becomes more hydrophobic. Rondeau et al. analyzed AGE-products 
of modified by glucose bovine serum albumin [25]. Using λex = 360 nm, they also have observed  
blue-shifted fluorescence indicating the reduction in the polarity of AGEs environment. 
Due to the glycation process fluorescence intensity decreased about 6 times for Trp residues  
(Δλ = 60 nm) and 2.5 times for Tyr residues (Δλ = 15 nm). The same tendency was also observed at  
T = 311 K and T = 313 K. These results may suggest a modification of the structure of bovine serum 
albumin by glycation, especially in tryptophanyl and tyrosyl residues environment, which can affect 
the main binding sites of albumin in subdomain IIA and/or IIIA (Sudlow’s site I and/or II), and also 
in subdomains IB and IIB. It is conventional in the fluorescence that the shift of position at maximum 
emission wavelength (λmax) corresponds to changes in polarity around the chromophores molecule. 
A blue-shift of λmax indicates the increase in hydrophobicity around chromophores while a red-shift 
of λmax implies increase in hydrophilicity and the chromophores are more exposed to the solvent 
molecules [22]. Using Δλ = 60 nm and Δλ = 15 nm, no changes in the maximum emission wavelengths 
on synchronous spectra of BSA and gBSA tryptophanyl and tyrosyl residues were observed (Figure 1) 
and no changes in the polarity around the indole group of Trp residues have been registered. It seems 
surprising especially that the maximum emission of Trp is highly sensitive to the local environment. 
In order to monitor the structural changes in the Trp microenvironment of BSA (Figure 3a) and 
gBSA (Figure 3b) tryptophanyl residues (Trp-135 and Trp-214), λex from 290 nm to 305 nm has been 
used and the spectral parameter A for BSA and gBSA has been calculated in the range temperature 
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between 309 K and 313 K (Table 1, Figure 3 in the inserts). In order to determine spectral parameter 
A it is necessary to use two wavelengths from the opposite edges of bandwidth, where steepness of 
the band is large. This causes that for the small change of wavelength the change in the fluorescence 
intensity is large. In the literature and in the present study the 320 nm and 365 nm wavelengths for 
proteins containing Trp residues have been used because they correspond to approximately half of 
the length of band steepness (ܣ =	 ிయమబ	೙೘ிయలఱ	೙೘). The spectral parameter A is the most sensitive indicator of 
spectral shifts which is less sensitive to experimental errors. As a consequence parameter A provides 
more accurate position of fluorescence spectra in comparison with a position of the maximum 
fluorescence (λmax) [26]. 
(a) (b)
Figure 3. Emission fluorescence spectra of: (a) non-glycated (BSA); and (b) glycated (gBSA) bovine 
serum albumin excited at λex = 290 nm, λex = 295 nm, λex = 300 nm and λex = 305 nm, T = 309 K. Inserts 
are plots of parameter ܣ = 	 ிయమబ	೙೘ிయలఱ	೙೘ versus the excitation wavelength at the temperature in the range 
between 309 K and 313 K for: (a) BSA; and (b) gBSA.  
Emission fluorescence spectra of gBSA Trp-135 and -214 residues differ from the Trp residue of 
non-glycated albumin for all excitation wavelengths (Figure 3). The change in the gBSA spectrum in 
comparison with BSA is significant especially at λex = 305 nm. With the increase of excitation 
wavelength from 290 nm to 305 nm spectral parameter A decreases 1.2 times at all temperatures 
(Table 1). It probably means that fluorescent spectra of Trp residues shift towards long wavelengths 
(red-shift). This phenomenon called red-edge excitation shift is caused by microheterogeneity in the 
tryptophan (Trp) environment and electronic coupling between the tryptophan indole and neighboring 
dipoles which result in a distribution of electronic transition energies of the Trp [27]. On the other 
hand, spectral parameter A decreases five times the increase of excitation wavelength, obtained for 
glycated albumin at all temperatures. However, the shape of gBSA Trp residue spectrum (Figure 3b) 
points out the phenomenon that at the excitation wavelength 365 nm the fluorescence comes probably 
from AGEs due to the BSA glycation by fructose. It can be concluded that spectral parameter A is a 
tool that confirms the presence of AGEs in BSA-fructose complex regardless of the temperature.  
At the excitation wavelength λex = 305 nm, spectral parameter A does not change with the change of 
temperature (0.21–0.22). This phenomenon means that the increase of temperature does not influence 
on AGEs concentration. 
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Table 1. The fluorescence intensity of BSA and gBSA at λem = 320 nm and λem = 365 nm; λex = 290 nm,  
λex = 295 nm, λex = 300 nm and λex = 305 nm; BSA, gBSA = 5 × 10−6 mol∙L−1; T = 309 K, T = 311 K and T = 313 K. 
Parameter A λex = 290 nm λex = 295 nm λex = 300 nm λex = 305 nm 
T = 309 K 
۴૜૛૙
۴૜૟૞ (BSA) ± SD 0.93 ± 0.02 0.87 ± 0.02 0.83 ± 0.03 0.77 ± 0.02 ۴૜૛૙
۴૜૟૞ (gBSA) ± SD 1.00 ± 0.01  0.74 ± 0.02 0.46 ± 0.05 0.21 ± 0.06 
T = 311 K 
۴૜૛૙
۴૜૟૞ (BSA) ± SD 0.96 ± 0.02 0.89 ± 0.02 0.85 ± 0.02 0.78 ± 0.03 ۴૜૛૙
۴૜૟૞ (gBSA) ± SD 1.02 ± 0.01 0.75 ± 0.02 0.47 ± 0.04 0.21 ± 0.05 
T = 313 K 
۴૜૛૙
۴૜૟૞ (BSA) ± SD 0.97 ± 0.01 0.90 ± 0.03 0.86 ± 0.03 0.79 ± 0.04 ۴૜૛૙
۴૜૟૞ (gBSA) ± SD 1.03 ± 0.02 0.75 ± 0.05 0.47 ± 0.04 0.22 ± 0.06 
SD = standard deviation. 
Another evidence for modification of BSA structure was the analysis of the second derivative 
spectra. Derivative spectroscopy can extract more information contained within a spectral distribution 
usually not accessible through the direct spectroscopic measurements and reduce the effect of much 
spectral interference [28]. Figure 4 presents gBSA emission spectrum (normgBSA) normalized to BSA 
and their second derivative fluorescence spectra for: (a) λex = 275 nm; and (b) λex = 295 nm. Before the 
determination of the second derivative spectra, the fluorescence spectra of gBSA was normalized to 
respective maxima fluorescence spectra of BSA, λem = 337 nm and λem = 339 nm for λex = 275 nm and  
λex = 295 nm, respectively. 
(a) (b)
Figure 4. Glycated albumin emission spectrum normalized to non-glycated (normgBSA) and their second 
derivative fluorescence spectra (2nd BSA, 2nd normgBSA) for: (a) λex = 275 nm; and (b) λex = 295 nm.  
The spectra were normalized to their respective maxima around λem = 340 nm, T = 309 K. 
The changes in the second derivative spectra in the wavelength range 370 nm–400 nm and the 
range below 320 nm indicate the structure reorganization around tryptophanyl (Trp-214 and Trp-135) and 
tyrosyl residues (Tyr) in serum albumin, respectively [29,30]. At λex = 275 nm, the second derivative 
fluorescence spectra of non-glycated bovine serum albumin exhibits two peaks maximum (at 
wavelengths 288 nm and 307 nm) and marked valleys at 295 nm and 328 nm, while the second derivative 
spectra of normalized glycated bovine serum albumin (normgBSA) has four peaks maximum (288 
nm, 305 nm, 315 nm and 328 nm) and four marked valleys (299 nm, 311 nm, 320 nm and 337 nm) 
(Figure 4a). At λex = 295 nm the second derivative fluorescence spectra of BSA exhibits only one peak 
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maximum (at wavelengths 304 nm) with marked valley at 329 nm and small shoulder from the red 
side of the peak, while the second derivative spectra of normgBSA has two peaks maximum (304 nm 
and 329 nm), two valleys (322 nm and 336 nm) and also one shoulder from the red side of the peak 
at wavelengths 304 nm (Figure 4b). Glycation of BSA causes changes in the second derivative 
fluorescence spectrum at both λex = 275 nm and λex = 295 nm (Figure 4a,b) indicating that Trp-214, 
Trp-135 and nineteen tyrosyl residues (Tyr) in bovine serum albumin participate in the process of 
glycation. The values of the second derivative fluorescence spectra for BSA and normgBSA were 
determined by peak to peak method (the distance from the positive peak maximum to the negative 
peak minimum) as an empirical parameter H (relative peak composition) defined by Mozo-Villarias 
[29,30]. The empirical parameter H is an indicator of the polarity changes around aromatic residues 
of proteins. The values of parameter H are collected in Table 2. 
Table 2. Relative peak composition (parameter H) of bovine serum albumin residues at λex = 295 nm 
and λex = 275 nm. 
 H275nm λmin (nm) λmax (nm) H295nm λmin (nm) λmax (nm)
BSA 0.426 295 307 0.018 387 395 
normgBSA 0.701 299 305 0.023 387 392 
Glycation of BSA causes the increase in polarity around the tryptophanyl (Trp-214 and Trp-135) 
(λex = 275 nm) and tyrosyl (Tyr) residues (λex = 295 nm) that was shown as an increase in the value of 
parameter H (Table 2). Kumar et al. compared the second derivative fluorescence spectra of 
somatostatin and serum albumin incubated with guanidine hydrochloride. They suggested that first 
derivative of a signal from the blue-wave spectrum is more sensitive to structural changes [29]. 
Qualitative analysis indicated that glycation of bovine serum albumin changes (reorganizes) the 
structure of macromolecule around both tryptophanyl and tyrosyl residues. The main glycation sites 
are located in the vicinity of known drug binding sites. Wa et al. have characterized the glycation 
adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry and found numerous residues of lysines, Lys-12, Lys-51, Lys-199, Lys-205, Lys-439 and 
Lys-538, to be modified through the formation of fructose-lysine [11]. In addition, some lysine 
residues of BSA glycated in vitro with glucose have been shown to be involved in the formation of 
versperlysine products [31]. Other studies revealed Lys-524 as the major glycation site in BSA [32,33] 
and also Lys-275, Lys-232 and Lys-396-constituted amino acids susceptible to glycated [32,34]. 
Though less abundant in the amino acid sequence of albumin than lysine residues (23 for 59 lysine 
residues), arginine residues can also be involved in glycation. The tryptic peptide mapping of modified 
human serum albumin, in vitro and in vivo, by methylglyoxal, indicated the major modification at  
Arg-410, which is located in drug binding site II. Minor arginine sites involved in glycation, such as  
Arg-114, Arg-160, Arg-186, Arg-218 and Arg-428, have also been identified [10]. It is noteworthy that 
the positions and architecture of fatty acids (FAs) binding sites on serum albumin have been also 
identified for these sites, in subdomains IB, IIIA, and IIIB [35,36]. Native bovine albumin exhibits  
two main binding sites for lipoic acid, an effective antioxidant, whereas methylglyoxal-modified 
protein shows three sequential binding sites with a reduction in affinity for the main one [37] therefore 
the influence of FAs on glycation process should be taken into account. Yamazaki et al. described strong 
affinity of fatty acids for albumin via several lysine and arginine sites. They observed the slight effect 
of oleate, laurate, caproate and linoleate binding on the glycation process [38]. Binding of fatty acids 
to albumin has an influence on its structure also in terms of binding parameters. Bojko et al. have 
analysed the influence of fatty acids and on drug-albumin binding [39]. They investigated that the 
presence of myristic acid alters the affinity between bovine serum albumin and drug. 
2.2. Effect of Glycation on Binding of Tolbutamide to Bovine Serum Albumin 
Hereby, we used BSA in order to prove the glycation of albumin mainly in subdomain IB. The 
complex between tolbutamide (TB) and non-glycated (BSA) and glycated (gBSA) bovine serum albumin 
has been studied using the fluorescence emission spectra recorded at the excitation wavelengths  
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λex = 275 nm and λex = 295 nm, respectively. The wavelength λex = 295 nm causes the excitation of two 
tryptophanyl residues in BSA, i.e., Trp-135 (localized in subdomain IB) and Trp-214 (localized in 
subdomain IIA) while wavelength λex = 275 nm excites not only tryptophanyl residues (Trp-135 and 
Trp-214), but also tyrosine residues mainly located in subdomains IB (Tyr-138, Tyr-140, Tyr-148,  
Tyr-150, Tyr-156, Tyr-157, and Tyr-161), IIA (Tyr-263) and IIIA (Tyr-401, Tyr-411, Tyr-452, and Tyr-497) 
[19]. Consequently, both types of fluorophores and/or their microenvironment may participate in 
ligand-albumin interaction. Intramolecular interactions of TB with albumin (BSA and gBSA) were 
studied using the quenching fluorescence method. 
Based on the Stern-Volmer plot (Equation (1)), the mode of the interaction between TB and both 
BSA and gBSA was analyzed (Figure 5). ிబி  dependence on TB concentration when only tryptophanyl 
(Trp-135 and Trp-214) residues have been excited (Figure 5b) displays negative deviation from 
linearity for both BSA and gBSA. It does mean that there are fluorophores accessible to the quencher 
(TB) with different value of the Stern-Volmer constant KSV [40]. Trp-135 and Trp-214 are located in 
different microenvironment therefore the accessibility of TB to these fluorophores also is not the 
same. Negative deviation of Stern-Volmer plot from linearity allows to estimate that subdomain IIA 
and IB are involved in TB-serum albumin interaction. However, the linear course of Stern-Volmer plot 
obtained for gBSA (λex = 275 nm) results from the weak quenching of gBSA (~4%) by TB (Figure 5a). 
(a) (b)
Figure 5. The Stern-Volmer plots of ୊బ୊  vs. (TB) (mol∙L
−1) for TB-BSA ( ) and TB-gBSA ( ) complex: 
(a) λex = 275 nm; and (b) λex = 295 nm; T = 309 K. The error bars are smaller than the symbols. 
Stern-Volmer curve modified by Lehrer (Equation (2)) was plotted to determine the effective 
Stern-Volmer constants KSV (L∙mol−1) for tolbutamide complexes with BSA and gBSA. The data have 
been collected in Table 3. The KSV constant determined for TB-gBSA system is higher than that for the 
TB-BSA system excited at 295 nm for each applied temperature. This phenomenon shows that 
fructose glycation of BSA changes the fluorophores conformation and makes the tolbutamide 
diffusion to Trp-135 and Trp-214 easier. The KSV constant determined for TB-gBSA system is smaller 
than for the TB-BSA system excited at 275 nm in 309 K, 311 K temperature and higher in 313 K. This 
effect is difficult to explain because using λex = 275 nm excitation wavelength excites 22 fluorophores 
of BSA (20 Tyr and 2 Trp residues). 
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Table 3. The Stern-Volmer constant of protein fluorescence KSV, the association constant Ka for the 
ligand-albumin complex and number of binding sites ݊  determined for TB-BSA and TB-gBSA 
system; λex = 275 nm and λex = 295 nm. 
TB-BSA
T(K)  λex = 275 nm λex = 295 nm  
 KSV ± SD (L∙mol−1) Ka ± SD (L∙mol−1) n ± SD KSV ± SD (L∙mol−1) Ka ± SD (L∙mol−1) n ± SD
309 (6.04 ± 0.06) × 104 (7.88 ± 0.11) × 104 0.95 ± 0.02 (1.47 ± 0.03) × 104  (1.64 ± 0.04) × 104  1.00 ± 0.02 
311 (3.99 ± 0.01) × 104 (4.82 ± 0.30) × 104 0.87 ± 0.04 (1.40 ± 0.01) × 104  (1.55 ± 0.02) × 104  0.96 ± 0.01 
313 (1.78 ± 0.06) × 104 (1.98 ± 0.06) × 104 0.83 ± 0.05 (1.11 ± 0.02) × 104  (1.20 ± 0.02) × 104  0.93 ± 0.03 
TB-gBSA
T(K)  λex = 275 nm   λex = 295 nm  
 KSV ± SD (L∙mol−1) Ka ± SD (L∙mol−1) n ± SD KSV ± SD (L∙mol−1) Ka ± SD (L∙mol−1) n ± SD
309 (0.56 ± 0.01) × 104 (0.42 ± 0.02) × 104 1.09 ± 0.05 (5.22 ± 0.04) × 104  (6.61 ± 0.08) × 104  0.91 ± 0.02 
311 (1.15 ± 0.06) × 104 (1.24 ± 0.06) × 104 0.88 ± 0.04 (5.02 ± 0.02) × 104  (6.37 ± 0.05) × 104  0.90 ± 0.03 
313 (2.39 ± 0.03) × 104 (2.79 ± 0.02) × 104 0.85 ± 0.05 (3.69 ± 0.01) × 104  (4.43 ± 0.01) × 104  0.87 ± 0.04 
SD = standard deviation. 
The analysis of TB interactions with BSA and gBSA excited at λex = 275 nm (Figure 6a) and  
λex = 295 nm (Figure 6b) have been presented with the use of a binding isotherm.  
Nonlinear shape of the binding isotherms of BSA and gBSA at both exciting wavelengths  
(λex = 275 nm and λex = 295 nm) in the presence of tolbutamide (Figure 6a,b) indicated mixed (specific 
and nonspecific) nature of TB interaction with both albumins [41]. 
 
(a) (b)
Figure 6. Binding isotherms of non-glycated (BSA, ) and glycated (gBSA, ) bovine serum albumin 
at 5 × 10−6 mol∙L−1 concentration with TB at 1 × 10−5 mol∙L−1–1 × 10−4 mol∙L−1 concentrations: (a) λex = 275 nm 
and (b) λex = 295 nm; T = 309 K. The error bars are smaller than the symbols. 
The quantitative analysis of binding parameters describes the affinity of TB to the binding site. 
The Klotz Equation (3) allows determining the association constants Ka (L∙mol−1) and the number of 
binding sites (݊) for the independent classes of TB binding sites in non-glycated and glycated albumin 
molecule. Only one class of binding site was found for TB in both BSA and gBSA structures (λex = 275 nm 
and λex = 295 nm) with the following Ka constants values have been calculated: Ka(275 nm) (7.88 ± 0.11) × 
104 L∙mol−1, Ka(295 nm) (1.64 ± 0.04) × 104 L∙mol−1 and Ka(275 nm) (0.42 ± 0.02) × 104 L∙mol−1, Ka(295 nm) (6.61 ± 0.08) × 
104 L∙mol−1, respectively. Based on the obtained association constants we can conclude that glycation 
with fructose changes TB affinity towards bovine albumin. TB has a greater affinity for subdomain 
IIA and/or IB of glycated albumin than non-glycated protein (Table 3, λex = 295 nm). In addition, TB forms 
stronger complex with non-glycated than glycated albumin (Table 3, λex = 275 nm). The differences 
between the constants calculated for 275 nm and 295 nm are the results of the participation of different 
excited fluorophores, originating from different subdomains, in the formation of complexes. Moreover, 
the discrepancy in the values of binding constants calculated at λex = 275 nm and λex = 295 nm may be 
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explained by greater participation of tyrosyl (λex = 275 nm) or only tryptophanyl (λex = 295 nm) 
residues in the complex with tolbutamide. Binding of tolbutamide to non-glycated and glycated serum 
albumin has been also analyzed by Joseph et al. [42]. The main goal of their study was to examine the 
binding of tolbutamide to human serum albumin (HSA) at various levels of glycation by the use of 
high-performance affinity chromatography. They investigated that the binding of tolbutamide to all 
of tested preparates of glycated human serum albumin (gHSA) could be described by a two site model 
involving both strong and weak affinity interactions. Joseph et al. reported that the association equilibrium 
constants ܭ௔	 for TB at high affinity sites on gHSA were in the range of 0.8–1.2 × 105 L∙mol−1 and increased 
by 1.4-fold in going from normal HSA to mildly gHSA. Moreover, the Ka for TB increased by 1.1- to 
1.4-fold and by 1.2- to 1.3-fold in going from normal HSA to the gHSA samples at Sudow’s site II and I, 
respectively. It is noteworthy that we have registered the Ka values of the same order (104) despite 
the use of technique having different fundamentals like fluorescence spectroscopy. Michalcová and 
Glatz studied the binding of the first generation of sulfonylurea antidiabetics to HSA and its glycated form 
by capillary electrophoresis-frontal analysis [43]. They reported that the binding constants decreased in 
the sequence acetohexamide > tolbutamide > chlorpropamide > carbutamide both for normal and 
glycated human serum albumins, with glycated giving lower values. 
2.3. The Effect of Temperature on Stability of the TB-BSA and TB-gBSA Complexes 
Maximum wavelength λmax of TB-BSA spectrum at TB:BSA = 2:1; 8:1; 14:1 and 20:1 molar ratios 
does not depend on temperature in the range between 309 K and 313 K (data not shown). However, 
the rise of temperature from 309 K to 313 K caused the red-shift of TB-gBSA system maximum 
wavelength at all studied TB:gBSA molar ratios by 3–4 nm at 275 nm wavelength excitation, when all 
Tyr and Trp residues potentially fluoresce (Figure 7a) and by 2–3 nm towards blue-shift at 295 nm 
wavelength excitation, when only Trp residues fluoresce (data not shown). The red-shift of maximum 
wavelength λmax of TB-gBSA spectrum indicates the increase in fluorophore environment polarity of 
bovine serum albumin, while the blue-shift of λmax means that amino acid residues (Trps) are located 
in a more hydrophobic environment and are less exposed to the solvent due to the glycation. Changes 
in polarity around the fluorophore molecule with the increase in temperature range may be due to the 
destabilization of the tertiary structure of albumin. Moreover, the formation of TB-BSA and TB-gBSA 
complexes may affect the microenvironment of binding sites. This could result in the change of non-
glycated and glycated bovine albumin sensitivity to temperature. Furthermore, it is interesting to note 
that at T = 311 K the maximum wavelength (λmax) is different for the majority of molar ratios and decreases 
with the increase of TB:gBSA molar ratio (Figure 7b). 
The quenching curves of BSA and gBSA fluorescence excited at λex = 275 nm and λex = 295 nm in 
the presence of tolbutamide at three different temperatures have been presented in Figure 8. 
 
(a) (b)
Figure 7. (a) Dependence of emission maximum wavelength (λ୫ୟ୶	)	on temperature for TB-gBSA 
complex; and (b) dependence of λ୫ୟ୶		on TB-gBSA molar ratios for T = 311 K; TB:gBSA 2:1, 8:1, 14:1 
and 20:1 molar ratios. The error bars are smaller than the symbols. 
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(a) (b)
 
(c) (d)
Figure 8. Comparison of the quenching curves of: (a,b) BSA; and (c,d) gBSA, in the presence of TB at 
temperature in the range between 309 K and 313 K; (a,c) λex = 275 nm; and (b,d) λex = 295 nm. The 
error bars are smaller than the symbols. 
The course of these curves is temperature dependent and confirms the ability of tolbutamide 
molecule to receive the energy from excited fluorophores. As it is shown in Figure 8, the fluorescence 
of BSA and gBSA excited at λex = 275 nm is quenched by tolbutamide by 20.1%, 17.8%, 15.6% (Figure 8a) 
and 3.8%, 6.2%, 7.3% (Figure 8c) for 309 K, 311 K and 313 K, respectively (TB:albumin 20:1 molar 
ratio). At the same molar ratio, the fluorescence of these two albumins excited at λex = 295 nm is 
quenched by tolbutamide with a lower for TB:BSA and higher for TB:gBSA efficiency, i.e., 10.9%, 
12.1%, and 13% (Figure 8b); and 6.4%, 9.4%, and 10% (Figure 8d), respectively. This quenching 
phenomenon in the temperature range between 309 K and 313 K, more significant for BSA than gBSA 
(λex = 275 nm and λex = 295 nm), shows that the energy transfer from non-glycated to tolbutamide is 
easier than from glycated albumin and confirms the fact of TB-BSA complex formation in close 
proximity to excited fluorophores. The comparison of the quenching fluorescence curves of both 
proteins excited at λex = 275 nm and λex = 295 nm at all applied temperatures shows that fluorescence 
of BSA is quenched by TB to a greater extend at λex = 275 nm than λex = 295 nm. For glycated albumin 
the opposite effect was observed. The fluorescence of gBSA is quenched by TB to a greater extend at 
λex = 295 nm than λex = 275 nm. As these wavelengths excite different fluorophores in the albumin, 
more distinct decrease in fluorescence of protein excited at λex = 295 nm indicates that fructose 
glycated BSA molecule involves preferentially subdomain IIA and/or IB in binding process of 
tolbutamide. Moreover, the quenching effect of BSA and gBSA fluorescence in the presence of 
tolbutamide increases (Figure 8b–d) while for BSA excited at λex = 275 nm decreases (Figure 8a) with 
the increase of temperature from 309 K to 313 K. This effect suggests that structural modification of 
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bovine albumin due to glycation causes the changes in the excited fluorophores environment, mainly 
in the region of tyrosine residues. 
Stern-Volmer analysis is a useful tool for estimation of the accessibility of albumin fluorophores 
(Trp and Tyr residues) to the drug molecules and for understanding the involved quenching mechanism 
(dynamic and/or static). Figure 9a,d presents the Stern-Volmer plots for TB-BSA (Figure 9a,b) and  
TB-gBSA (Figure 9c,d) complexes at λex = 275 nm (Figure 9a,c) and λex = 295 nm (Figure 9b,d) 
excitation wavelengths, respectively. 
The course of Stern-Volmer curves obtained for BSA and gBSA in the presence of tolbutamide 
varies depending on the excitation wavelength (λex = 275 nm and λex = 295 nm) in the temperature 
range between 309 K and 313 K. It is noteworthy that below TB concentration 3 × 10−5 mol∙L−1 at all 
temperatures and at 295 nm excitation wavelength the Stern-Volmer plot showed a linear relationship 
between quenching effect ቀF0F ቁ of non-glycated BSA and TB concentration (Figure 9b). According to 
Efting and Ghiron’s theory, it means that Trp-214 and Trp-135 excited state is quenched both by the 
collisional mechanism and complex formation [40]. A negative deviation from a straight course of 
Stern-Volmer curves were found for TB-glycated BSA complexes at all applied TB concentration 
range (Figure 9d). The negative deviation in the Stern-Volmer curve course above TB:BSA and 
TB:gBSA 4:1 molar ratio points out that both Trp-135 and Trp-214 microenvironment interacts with 
TB while below TB:BSA and TB:gBSA 4:1 molar ratio a linear course of Stern-Volmer plots (λex = 275 nm, 
T = 309 K and T = 313 K) has been registered (Figure 9a). As for the molar ratio TB:gBSA <6:1 molar 
ratio a linear course of Stern-Volmer plot at the temperature T = 311 K was observed (Figure 9c). Akbay 
et al. explained that, during dynamic quenching, the ligand may penetrate the surrounding of 
albumin molecule and then the fluorescence quenching is caused by the collision of the quencher 
molecule and fluorophores [44]. However static quenching proves that all excited amino acids 
residues are equally available for ligand or alternatively selected amino acid residue dominates the 
fluorescence [45]. The fluorescence quenching process depends on the nature of the fluorophores and 
the quencher molecule. Our study suggests that glycation of BSA by fructose influences on the tertiary 
structure of albumin and modifies the fluorescence quenching mechanism of the TB-BSA complex. 
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(c) (d)
Figure 9. Comparison of the Stern-Volmer curves of ிబி  vs. TB concentration (mol∙L
−1) for: (a,b) TB-BSA; 
and (c,d) TB-gBSA complex in the temperature range between 309 K and 313 K; (a,c) λex = 275 nm; and 
(b,d) λex = 295 nm. The error bars are smaller than the symbols. 
Due to general deviation of Stern-Volmer plot from linearity the quenching process was analyzed 
according to the Stern-Volmer equation modified by Lehrer (Equation (2)) and can be determined by 
the value of quenching rate constants kq (L∙mol−1∙s−1) (Equation (1)). The Stern-Volmer constant KSV 
(L∙mol−1) obtained based on the Equation (2) allows to estimate the distance between the excited 
fluorophore/s and ligand molecule. Reduction in KSV value means the increase in a distance between 
albumin tryptophanyl and tyrosyl groups and ligand molecule. The Stern-Volmer constant values 
calculated for TB-BSA and TB-gBSA system at T = 309 K, T = 311 K and T = 313 K temperatures have 
been collected in Table 3. The decrease in KSV values with the rise of the temperature (from 309 K to 
313 K) shows the weakening of tolbutamide accessibility to the tryptophanyl and tyrosyl residues of 
non-glycated and glycated bovine serum albumin (except TB-gBSA at λex = 275 nm). This phenomenon 
suggests the changes in the protein structure due to the temperature effect, more significant observed at 
λex = 275 nm than at λex = 295 nm. Considering the Stern-Volmer constant KSV and the fluorescence 
lifetime of albumins τ0 in the absence of quencher of the order 104 L∙mol−1 and 10−9 s, respectively, the 
quenching rate constant kq was of the order 1013 L∙mol−1∙s−1, which largely exceeds the accepted limit 
of the rate constant of the diffusional quenching implying biopolymers kq = 2 × 1010 L∙mol−1∙s−1 [46]. 
This observation supports the fact that the experimental quenching of BSA and gBSA fluorescence is 
due to a predominantly static process resulting in the formation of TB-BSA and TB-gBSA complex. 
The association constants Ka (L∙mol−1) and the number of binding sites ݊ for the independent 
class of drug binding sites in the bovine albumin have been determined using Klotz Equation (3). The 
binding parameters (Ka and n) for TB-BSA and TB-gBSA (λex = 275 nm, λex = 295 nm) system for 
specified temperatures were determined and collected in Table 3. Due to the value of determination 
coefficients larger than 0.99 we concluded that that the interaction between TB and BSA/gBSA is 
consistent with the site-binding model defined by Klotz Equation (3). The linear Klotz plots (data not 
shown) at both λex = 275 nm and λex = 295 nm, at all analyzed temperatures (T = 309 K, T = 311 K and 
T = 313 K) show that TB occupies in non-glycated albumin only one class of binding sites in BSA 
subdomain IB or IIA. We observed that glycation of bovine serum albumin did not change the shape 
of Klotz plots. It means that TB binds to structural altered albumin (glycated BSA) first class of 
binding sites, similarly as to non-glycated. Based on the variations in association constants Ka values 
(Table 3), the changes in BSA binding ability towards tolbutamide under the glycation by fructose 
process have been confirmed. Subdomain IIA and IB of fructose glycated BSA has enhanced affinity 
towards tolbutamide at all applied temperatures than non-glycated BSA. Mentioned subdomains of 
fructose glycated BSA (λex = 275 nm) diminish affinity for tolbutamide. With the increase of 
temperature, the association constants ܭ௔ values drop for TB-BSA (λex = 275 nm and λex = 295 nm) 
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and TB-gBSA (λex = 295 nm) complexes and this phenomenon is typical for complex formation. For 
the TB-gBSA system excited at λex = 275 nm, not only Ka but also KSV values increase with the increase of 
temperature. This phenomenon suggests that collisional quenching of gBSA fluorescence dominates the 
fluorescence quenching than complex formation. 
2.4. Nature of the Binding Forces for TB-BSA and TB-gBSA Complex Formation 
The interaction of ligand and albumin may involve hydrophobic forces, electrostatic interactions, 
van der Waals interactions and formation of hydrogen bonds. Thermodynamic parameters of interaction, 
free energy (ΔG), enthalpy (ΔH) and entropy changes (ΔS) are essential to interpret the binding mode. 
The thermodynamic parameters for the interaction of tolbutamide (TB) with non-glycated (BSA) and 
glycated (gBSA) albumin have been calculated and collected in Table 4. The negative ΔG values obtained 
based on the Equation (4) for all TB-BSA and TB-gBSA complexes formed at T = 309 K, T = 311 K and  
T = 313 K means that in this temperature range the complex tolbutamide-bovine serum albumin forms 
spontaneously. At the excitation wavelength λex = 275 nm the positive values of ΔH and ΔS calculated 
on the basis of Equations (5) and (6) indicate that hydrophobic forces may play a major role in the 
binding between TB and gBSA while the negative enthalpy (ΔH) and negative entropy (ΔS) for the 
interaction between TB and BSA indicate that the hydrogen bonding and van der Waals forces play 
a major role in the binding process (Table 4). Additionally, involvement of the electrostatic forces 
usually provides a negative and positive ΔH and ΔS, respectively [47]. At the excitation wavelength  
λex = 295 nm the calculation of ΔH and ΔS was not possible to obtain because the R2 = 0.53–0.63 values 
indicate no “linear” relationship (for straight line regression). 
Table 4. The thermodynamic parameters of formation of the TB-BSA and TB-gBSA complex; λex = 275 nm 
and λex = 295 nm. 
   TB-BSA   
T (K)  λex = 275 nm λex = 295 nm  
 
ΔG ± SD 
(kJ∙mol−1) ΔH ± SD (J∙mol
−1) ΔS ± SD (J∙mol−1∙K−1) ΔG ± SD 
(kJ∙mol−1) 
ΔH ± SD 
(J∙mol−1) 
ΔS ± SD 
(J∙mol−1∙K−1) 
309 −28.97 ± 0.03   −24.93 ± 0.06   
311 −27.88 ± 0.16 −277.69 ± 47.22 −804.21 ± 151.81 −24.95 ± 0.03 ---*) ---*) 
313 −25.74 ± 0.07   −24.44 ± 0.04   
   TB-gBSA    
T (K)  λex = 275 nm   λex = 295 nm  
 
ΔG ± SD 
(kJ∙mol−1) ΔH ± SD (J∙mol
−1) ΔS ± SD (J∙mol−1∙K−1) ΔG ± SD (kJ∙mol−1) 
ΔH ± SD 
(J∙mol−1) 
ΔS ± SD 
(J∙mol−1∙K−1) 
309 −24.43 ± 0.12   −28.51 ± 0.03   
311 −24.37 ± 0.12 377.87 ± 31.68 1292.58 ± 101.84 −28.60 ± 0.02 ---*) ---*) 
313 −26.60 ± 0.02   −27.84 ± 0.01   
SD, standard deviation; *), unable to calculate. 
3. Materials and Methods 
3.1. Reagents 
Crystallized, lyophilized and high purity bovine serum albumin (BSA, Lot No. 8234H) with fatty 
acids (fraction V) was purchased from MP Biomedicals LLC (Illkirch, France). Tolbutamide (TB, Lot 
No. SLBC2764V) was provided by Sigma-Aldrich Chemical Co. (Darmstadt, Germany). D(-)-fructose 
(FRC, Lot No. A0299881), Tris (hydroxymethyl)aminomethane pure p.a., hydrochloric acid 0.1 mol∙L−1 
(HCl) were obtained from POCH S.A. (Gliwice, Poland). The membrane filter with 0.20 μm pore size 
(30 mm in diameter, non-pyrogenic) and methanol were purchased from Merck KGaA (Darmstadt, 
Germany). All reagents and solvents were of analytical reagent grade. 
3.2. In Vitro Glycation of BSA 
Glycated protein (gBSA) was prepared in vitro by incubation of 5 × 10−6 mol∙L−1 bovine serum 
albumin (BSA) in Tris-HCl buffer (0.05 mol∙L−1, pH 7.4 ± 0.1) containing 0.015 mol∙L−1 sodium azide 
Molecules 2017, 22, 569 15 of 19 
 
in the presence of 0.10 mol∙L−1 D(-)-fructose (FRC). The reaction mixture was filtered through the 
membrane filter with 0.20 μm pore size into sterile capped test tubes and incubated at 310 K for 21 days. 
Control sample of 5 × 10−6 mol∙L−1 BSA was made from the same stock BSA solution as glycated BSA 
probe and treated similarly but in the absence of reducing sugar. After incubation the protein stock 
solutions (control non-glycated and glycated BSA) were extensively overnight dialyzed at room 
temperature against Tris-HCl buffer with three exchanges to remove residual sugar and again filtered 
by membrane filter. Fluorescence spectra were recorded 60 min after preparation of the solutions. 
The pH of protein solution was confirmed with pH meter (FEP20 Metler Toledo). The purity of 
albumin has been studied and the absorbance at 255 nm and 280 nm ratio was less than 0.5, indicating 
the high content of protein. 
3.3. Fluorescence Spectroscopy 
From the series of drug-protein interaction study, fluorescence methods are useful tool due to the 
high sensitivity, rapidity and ease of implementation. These methods allow for examination of BSA 
interaction with drugs within subdomains IIA and IB. The fluorescence measurements of the samples 
were recorded in the temperature range between 309 K and 313 K using JASCO fluorescence 
spectrophotometer FP-6500 equipped with Peltier thermostat. A quartz cuvette with 10 mm path 
length was used for all fluorescence experiments. The emission fluorescence spectra of non-glycated 
(BSA) and glycated (gBSA) bovine serum albumin tryptophanyl (Trp) and tyrosyl (Tyr) residues were 
recorded at the excitation wavelength λex = 275 nm while the fluorescence spectra of tryptophanyl 
residues were measured at λex = 295 nm. The measurement range of all emission spectra was recorded 
from 310 nm to 400 nm and widths of both the excitation and emission slit were set at 3.0 nm. 
Excitation at λex = 335 nm was applied for measurement of the fluorescent Advanced Glycation  
End-products (AGEs) in BSA and gBSA and for this experiment excitation and emission slit widths 
were 5.0 nm. The synchronous fluorescence spectra of BSA and gBSA fluorophores were obtained 
considering the wavelength intervals ∆λ = 15 nm (λex = 265 nm–315 nm) and ∆λ = 60 nm (λex = 250 nm 
–440 nm), where ∆λ means the difference between emission (λem) and excitation (λex) wavelength. 
Fluorescence second derivative spectra were obtained by the use of Spectra Analysis software 
(Spectra Manager, version 1.55.00, Jasco Corporation, Easton, MD, USA) using Savitzky and Golay 
algorithm, second order of polynomial and 15 data points. To obtain the complex TB-BSA and TB-
gBSA, the bovine serum albumin solution was titrated using Hamilton syringe directly into the 
cuvette by the addition of increasing aliquots of TB stock solution (1 × 10−2 mol∙L−1). Tolbutamide 
stock solution was dissolved in methanol (not exceeding 1% v/v in the final concentration). The BSA 
and gBSA concentration in those experiments was fixed at 5 × 10−6 mol∙L−1 and the molar ratios 
TB:BSA and TB:gBSA were varied to 20:1. Light scattering caused by buffer was subtracted from 
samples fluorescence in each spectrum using software supplied by JASCO (Spectra Manager). 
Tolbutamide absorbance at the used concentrations was below 0.05; therefore, no correction of inner 
filter effect in fluorescence spectra has been applied [48]. 
3.4. Calculation of the Stern-Volmer and Association Constants 
Using fluorescence data, the quenching curves (ிிబ vs. TB:albumin molar ratio) of non-glycated (BSA) 
and glycated (gBSA) bovine serum albumin in the presence of tolbutamide (TB) have been plotted. 
The quenching effect of BSA and gBSA fluorescence was analyzed on the basis of the Stern-Volmer 
equation, which describes ligand movement within the fluorophore microenvironment [46]:  
F଴
F = 1 + k୯τ଴ ∙ L = 1 + Kୗ୚ ∙ L (1) 
where ܨ଴  and ܨ	  are the fluorescence intensities in the absence and presence of the quencher, 
respectively; ݇௤  is the bimolecular quenching rate constant (L∙mol−1∙s−1); τ଴  is the average 
fluorescence lifetime of a molecule in the absence of quencher τ0 = 6.2 × 10-9 s [35]; and KSV is the  
Stern-Volmer constant (L∙mol−1); L is the ligand (TB) concentration (mol∙L−1). 
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To analyze the interactions between the drug and bovine serum albumin (BSA, gBSA) in the high 
affinity binding sites, the Stern-Volmer (KSV) and association (Ka) constants have been determined. The 
Stern-Volmer constant KSV was calculated using Stern-Volmer equation modified by Lehrer [49]: 
F଴
∆F =
1
L ∙
1
fୟ ∙
1
Kୗ୚ +
1
fୟ (2) 
where F଴  and F are the relative fluorescence intensities at fixed wavelength in the absence and 
presence of the quencher, respectively; ΔF is the difference between F and F0; ΔF = F0 − F; fa is the 
fractional maximum fluorescence accessible for the quencher; KSV is the Stern-Volmer constant 
(L∙mol−1); and L is the ligand concentration (mol∙L−1). 
Association constants Ka were calculated by the use of Klotz equation [50]: 
1
ݎ =
1
݊ +
1
݊ ∙ Kୟ ∙ L୤ (3) 
where ݎ = 	 ୐ౘ୆ୗ୅ is the number of ligands moles bound per mole of protein molecule; [L] = [Lb] + (Lf), 
Lb and Lf are the bound and free drug concentration; BSA is serum albumin concentration (mol∙L−1); 
Lୠ = ∆୊∆୊ౣ౗౮ ∙ BSA୲୭୲ୟ୪; ΔFmax (maximal fluorescence change with complete saturation) is evaluated from 
the linear part of the ଵ∆୊ versus 
ଵ
୐; ݊ is the number of binding sites for the independent class of drug 
binding sites in the albumin molecule; and Ka is the association constant (L∙mol−1). 
Binding isotherms of TB to albumins have been obtained based on the graph of the function  
r = f(Lf) [51]. 
3.5. Calculation of the Thermodynamic Parameters 
Thermodynamic parameters, i.e., free energy (G), enthalpy (H) and entropy changes (S) are essential 
to characterize ligand (TB)—albumin (BSA, gBSA) interaction. Changes of free energy (ΔG) were 
calculated from the van’t Hoff equation: 
∆G = −RTlnKୟ ൤
J
mol൨ (4) 
where R is the gas constant R = 8.314 J∙(molK)−1; T is the experimental temperature (K); and Ka is the 
association constant at corresponding T. 
The enthalpy (ΔH) and entropy changes ΔS were calculated from the Equations (5) and (6), 
respectively: 
݈݊ KଶKଵ = ൤
1
Tଵ −
1
Tଶ൨ ∙
∆H
R  (5) 
where K1 and K2 are the association constants at T1 and T2 temperatures, respectively. 
∆G = ∆H − T ∙ ∆S (6) 
3.6. Statistics 
The mean and relative standard deviation (SD) was calculated from three independent experiments 
unless otherwise indicated. Points without error bars indicate that SD was less than the size of the symbol. 
4. Conclusions 
Glycation is a general spontaneous process in proteins that has significant impact on their physical 
and functional properties. These changes in protein properties could be related to several pathological 
consequences such as diabetic and non-diabetic cardiovascular diseases, cataract, renal dysfunction 
and Alzheimer’s disease. The work presented in this study can form an important tool in assessing 
the pharmacological properties of tolbutamide (TB) used in diabetic patients. Based on the 
fluorescence analyses, it was concluded that: (i) the structure of bovine serum albumin is modified 
by glycation, especially in tryptophanyl and tyrosyl residues environment which can affect the main 
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binding sites of albumin in subdomain IIA and/or IIIA (Sudlow’s site I and/or II), as well as in 
subdomains IB and IIB; (ii) glycation of BSA causes the increase in polarity of Trp-214, Trp-135 and 
Tyr residues environment; (iii) in the interaction of tolbutamide with non-glycated (BSA) and 
glycated (gBSA) bovine serum albumin, the tryptophanyl and tyrosyl residues take part; (iv) a mixed 
(specific and nonspecific) nature of TB interaction with BSA and gBSA and only nonspecific with 
gBSA has been described; (v) the increase in association constants Ka (L∙mol−1) in TB-gBSA vs.  
TB-BSA complexes means that in vitro glycated albumin has a higher affinity towards TB in 
comparison with non-glycated bovine albumin, and the rise of Ka values observed for TB-gBSA 
complex can be explained by the presence of an additional interaction (e.g., electrostatic or hydrogen) 
as a result of the binding sites conformational changes by glycation; (vi) with the increase of 
temperature, the association constants Ka (L∙mol−1) values drop for TB-BSA and TB-gBSA complex 
besides TB-gBSA (λex = 275 nm), which confirms the phenomenon that quenching of BSA fluorescence 
proceeds via the formation of complex in a ground state; and (vii) temperature dependence suggests 
the important role of van der Waals forces and hydrogen bonding in hydrophobic interactions 
between tolbutamide and both glycated and non-glycated albumin. 
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